[ORGANIZATION]
Wegovy
Featured in 5 tracked stories · first seen
Situations
German health and wellbeing trends
27 clusters · 78 sources · last updated
Latest: German health law classifies weight‑loss drugs as lifestyle medicines
2026 surveys show German youths are less worried about climate change while millennial parents report rising anxiety and up to one‑third of adolescents experience mental‑health problems. Problematic drinking affects abou
Novo Nordisk obesity portfolio: EU approval, legal fight
93 clusters · 431 sources · last updated
Latest: US Medicare Launches GLP-1 Bridge Program to Cut Drug Costs
Novo Nordisk’s obesity portfolio keeps expanding. The European Commission confirmed marketing authorisation for the once‑daily 25 mg oral semaglutide (Wegovy) tablet, the first oral GLP‑1 approved for weight management i
GLP‑1 market, usage & emerging safety signals
175 clusters · 628 sources · last updated
Latest: GLP-1 weight‑loss drugs linked to hair loss and higher divorce rates
GLP‑1 receptor agonists have become mainstream weight‑loss treatments, now used in primary‑care, tele‑health and covered by Medicare‑CMS, with market value projected near $105 billion by 2030. Observational BMJ data on ≈
Also covered in
-
German endocrinologist Prof. Norbert Stefan on weight‑cycling risks and GLP‑1 drugs
[HEALTH] · 5 sources ·